Inhibition of Lewis Lung Carcinoma Growth by Toxoplasma Gondii Through Induction of Th1 Immune Responses and Inhibition of Angiogenesis

Overview

Journal J Korean Med Sci

Specialty General Medicine

Date 2007 Dec 6

PMID 17923753

Citations 42

Authors

Ju Ock Kim

Sung Soo Jung

Sun Young Kim

Tae Yun Kim

Dae Whan Shin

Jae Ho Lee

Young Ha Lee

Affiliations

Soon will be listed here.

Abstract

Toxoplasma gondii is an obligate intracellular protozoan parasite that induces antitumor activity against certain types of cancers. However, little information is available regarding the immunologic mechanisms that regulate these effects. For this purpose, C57BL/6 mice were administered either the T. gondii Me49 strain orally or Lewis lung carcinoma (LLC) cells intramuscularly. Survival rates, tumor size, histopathology, and immune responses were determined for each group, and angiogenesis was evaluated by in vivo Matrigel plug assay. Toxoplasma-infected (TG-injected) mice survived the entire experimental period, whereas cancer cell-bearing (LLC-injected) mice died within six weeks. Mice injected with both T. gondii and cancer cells (TG/LLC-injected group) showed significantly increased survival rates, CD8+ T-cell percentages, IFN-gamma mRNA expression levels, serum IgG2a titers, and CTL responses as compared to the LLC-injected mice. In addition, angiogenesis in the TG/LLC-injected mice was notably inhibited. These effects in TG/LCC-injected mice were similar or were increased by the addition of an adjuvant, Quil-A. However, TG/LLC-injected mice showed decreased percentages of CD4+ and CD8+ T cells, IFN-gamma mRNA expression levels, and serum IgG1 and IgG2a titers as compared to TG-injected mice. Taken together, our results demonstrate that T. gondii infection inhibits tumor growth in the Lewis lung carcinoma mouse model through the induction of Th1 immune responses and antiangiogenic activity.

Citing Articles

Anti-tumor effects of Toxoplasma gondii and antigen-pulsed dendritic cells in mice bearing breast cancer.

Kim B, Choi H, Lee J, Choi I, Yuk J, Cha G Parasites Hosts Dis. 2025; 63(1):37-49.

PMID: 40045679 PMC: 11895089. DOI: 10.3347/PHD.24082.

Neospora caninum Inhibits Lewis Cancer and B16f10 Melanoma Lung Metastasis Development by Activating the Immune Response in Murine Models.

Qian W, Chen Y, Li C, Li X, Lv C, Jia Y Acta Parasitol. 2025; 70(1):52.

PMID: 39918646 DOI: 10.1007/s11686-025-00996-2.

Toxoplasma gondii-Derived Exosomes: A Potential Immunostimulant and Delivery System for Tumor Immunotherapy Superior to Toxoplasma gondii.

Zhao L, Sun Q, Wang C, Liu J, Yan X, Shao M Int J Nanomedicine. 2024; 19:12421-12438.

PMID: 39600411 PMC: 11590659. DOI: 10.2147/IJN.S483626.

Parasites revive hope for cancer therapy.

Eissa M, Salem A, El Skhawy N Eur J Med Res. 2024; 29(1):489.

PMID: 39367471 PMC: 11453045. DOI: 10.1186/s40001-024-02057-2.

Parasite-enhanced immunotherapy: transforming the "cold" tumors to "hot" battlefields.

Xie Y, Wang J, Wang Y, Wen Y, Pu Y, Wang B Cell Commun Signal. 2024; 22(1):448.

PMID: 39327550 PMC: 11426008. DOI: 10.1186/s12964-024-01822-4.

References

Tanaka M, Saijo Y, Sato G, Suzuki T, Tazawa R, Satoh K . Induction of antitumor immunity by combined immunogene therapy using IL-2 and IL-12 in low antigenic Lewis lung carcinoma. Cancer Gene Ther. 2000; 7(11):1481-90. DOI: 10.1038/sj.cgt.7700251. View

Blattman J, Greenberg P . Cancer immunotherapy: a treatment for the masses. Science. 2004; 305(5681):200-5. DOI: 10.1126/science.1100369. View

Lee Y, Kasper L . Immune responses of different mouse strains after challenge with equivalent lethal doses of Toxoplasma gondii. Parasite. 2004; 11(1):89-97. DOI: 10.1051/parasite/200411189. View

Bertram J, Janik P . Establishment of a cloned line of Lewis Lung Carcinoma cells adapted to cell culture. Cancer Lett. 1980; 11(1):63-73. DOI: 10.1016/0304-3835(80)90130-5. View

Hibbs Jr J, Lambert Jr L, Remington J . Resistance to murine tumors conferred by chronic infection with intracellular protozoa, Toxoplasma gondii and Besnoitia jellisoni. J Infect Dis. 1971; 124(6):587-92. DOI: 10.1093/infdis/124.6.587. View

Lee Y, Yang H, Shin K, Choi H, Jung S, Kim Y . Suppression of tumor growth by a new glycosaminoglycan isolated from the African giant snail Achatina fulica. Eur J Pharmacol. 2003; 465(1-2):191-8. DOI: 10.1016/s0014-2999(03)01458-4. View

Suzuki Y, Muto M, Kobayashi A . Antitumor effect of formalin-fixed Toxoplasma gondii organisms on EL4 lymphoma in Toxoplasma-infected mice. J Biol Response Mod. 1986; 5(4):288-93. View

Dietrich A, Becherer L, Brinckmann U, Hauss J, Liebert U, Gutz A . Particle-mediated cytokine gene therapy leads to antitumor and antimetastatic effects in mouse carcinoma models. Cancer Biother Radiopharm. 2006; 21(4):333-41. DOI: 10.1089/cbr.2006.21.333. View

Kimura Y, Kido T, Takaku T, Sumiyoshi M, Baba K . Isolation of an anti-angiogenic substance from Agaricus blazei Murill: its antitumor and antimetastatic actions. Cancer Sci. 2004; 95(9):758-64. PMC: 11159378. DOI: 10.1111/j.1349-7006.2004.tb03258.x. View

10.

Sharma S, Stolina M, Luo J, Strieter R, Burdick M, Zhu L . Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo. J Immunol. 2000; 164(9):4558-63. DOI: 10.4049/jimmunol.164.9.4558. View

11.

Raez L, Fein S, Podack E . Lung cancer immunotherapy. Clin Med Res. 2005; 3(4):221-8. PMC: 1288407. DOI: 10.3121/cmr.3.4.221. View

12.

Collins L, Haines C, Perkel R, Enck R . Lung cancer: diagnosis and management. Am Fam Physician. 2007; 75(1):56-63. View

13.

Suzuki Y, Kobayashi A . Antitumor effect of intralesional injection with formalin-fixed Toxoplasma gondii organisms on Lewis lung carcinoma in Toxoplasma-infected mice. Cancer Lett. 1985; 25(3):247-54. DOI: 10.1016/s0304-3835(15)30003-3. View

14.

Choi Y, Jeon Y, Kang J, Chung J, Schmidt M, Kim A . MIDGE/hNIS vaccination generates antigen-associated CD8+IFN-gamma+ T cells and enhances protective antitumor immunity. Int J Cancer. 2007; 120(9):1942-50. DOI: 10.1002/ijc.22567. View

15.

Denkers E . T lymphocyte-dependent effector mechanisms of immunity to Toxoplasma gondii. Microbes Infect. 1999; 1(9):699-708. DOI: 10.1016/s1286-4579(99)80071-9. View

16.

Varga A, Presber W, Von Baehr V, von Baehr R, Lucius R, Volk D . Toxoplasma infection and cell free extract of the parasites are able to reverse multidrug resistance of mouse lymphoma and human gastric cancer cells in vitro. Anticancer Res. 1999; 19(2A):1317-24. View

17.

Hunter C, Yu D, Gee M, Ngo C, Sevignani C, Goldschmidt M . Cutting edge: systemic inhibition of angiogenesis underlies resistance to tumors during acute toxoplasmosis. J Immunol. 2001; 166(10):5878-81. DOI: 10.4049/jimmunol.166.10.5878. View

18.

Petersen E . Toxoplasmosis. Semin Fetal Neonatal Med. 2007; 12(3):214-23. DOI: 10.1016/j.siny.2007.01.011. View

19.

Lee H, Lee H, Song G, Li G, Lee J, Lu J . 6-(1-Oxobutyl)-5,8-dimethoxy-1,4-naphthoquinone inhibits lewis lung cancer by antiangiogenesis and apoptosis. Int J Cancer. 2007; 120(11):2481-90. DOI: 10.1002/ijc.22486. View

20.

Behboudi S, Morein B . Quillaja saponin formulations that stimulate proinflammatory cytokines elicit a potent acquired cell-mediated immunity. Scand J Immunol. 1999; 50(4):371-7. DOI: 10.1046/j.1365-3083.1999.00603.x. View